ELSEVIER

Author Index for Volume 20

ACTION II Study Investigators, 493
Age-Related Eye Disease Study Research Group, 573
Albert JM, 253
Antckli T, 601
Armitage P, 207, 229

Bailey G, 133
Bain RP, 493
Barbiere C, 601
Bauer P, 519
Berger VW, 319
Bielory L, 52
Birjiniuk V, 601
Black D, 121
Booth D, 601
Borhani NO, 133
Borhani P, 133
Bozzette SA, 253
Breeson V, 133
Burack RC, 280
Burke GL, 267

Carlin JB, 547
Cartwright K, 493
Cha SS, 242
Chang MN, 353
Childhood Asthma Management Program Research Group, 91
Clark HD, 448
Concorde and Alpha Data and Safety Monitoring Committee, 207
Cosgrove N, 133
Curcovic V, 601

Darbyshire J, 567
Davis B, 121
Delta Data and Safety Monitoring Committee, 229
Desai M, 343
Diehr P, 267
Dippe S, 493
Dixon DO, 253
Drummond M, 479
Duggan C, 479
Duhaylongsod F, 601

Eagle K, 297
Eccles M, 479
Elbourne D, 149
Esposito R, 601
Exner DV, 319

Fawzi WW, 75
Fergusson D, 448
Feussner JR, 187
Fischer-Lapp K, 531
Fisher LD, 1, 16, 50
Floten H, 601
Frankel MR, 369
Franzosi MG, 194
Frederick M, 52
Freedman BI, 493
Freedman RR, 52
Freemantle N, 479
Freidlin B, 395

Garcia J, 149
Gaus W, 511
Gehan EA, 555
Geller NL, 52
George J, 280
George SL, 395
Geraci B, 121
Gifford DR, 369
Gimotty PA, 280
Goetghebeur E, 531
Goldman S, 297
Grover F, 601
Gu M, 423

Haines A, 479
Hanfelt JJ, 555
Hays MT, 187
Heitjan DF, 309
Hellemons BSP, 386
Henderson W, 601
Henderson WG, 297
Hershon K, 493
Hill R, 52
Hoffmeier M, 133
Högel J, 511
Holloway RG, 369
Huët C, 448
Hunsberger S, 52
Hunter DJ, 75

Ioannidis JPA, 253

Jacob RG, 52

Kaufmann P, 52
Kepner JL, 353
Knottnerus JA, 386
Korn EL, 395
Krieger S, 133
Krucoff M, 601
Krupski WC, 297

Lachin JM, 408
Lai TL, 423
Lakatos E, 121
Langenberg M, 386
Laupacis A, 448
Lavori PW, 187
LeBlanc M, 343
Lemmens TGJ, 386
Lesaffre E, 439
Levin J, 133
Lewis D, 601
Littooy F, 297
Liu PY, 343
Lodder J, 386
Lovato LC, 133
Lucke JC, 601

Mason J, 479
McAlister FA, 448
McFalls EO, 297
McIntosh M, 253
McNabb S, 297
Mooradian AD, 493
Moritz T, 297
Morrison DA, 601
Moyé L, 40, 121
Msamanga GI, 75
Murphy E, 601

Nazareth I, 479
Nicolis E, 194

Controlled Clinical Trials 20:620–621 (1999)
© Elsevier Science Inc. 1999
655 Avenue of the Americas, New York, NY 10010

0197-2456/99/$–see front matter

ELSEVIER

Author Index for Volume 20

ACTION II Study Investigators, 493
Age-Related Eye Disease Study Research Group, 573
Albert JM, 253
Antckli T, 601
Armitage P, 207, 229

Bailey G, 133
Bain RP, 493
Barbiere C, 601
Bauer P, 519
Berger VW, 319
Bielory L, 52
Birjiniuk V, 601
Black D, 121
Booth D, 601
Borhani NO, 133
Borhani P, 133
Bozzette SA, 253
Breeson V, 133
Burack RC, 280
Burke GL, 267

Carlin JB, 547
Cartwright K, 493
Cha SS, 242
Chang MN, 353
Childhood Asthma Management Program Research Group, 91
Clark HD, 448
Concorde and Alpha Data and Safety Monitoring Committee, 207
Cosgrove N, 133
Curcovic V, 601

Darbyshire J, 567
Davis B, 121
Delta Data and Safety Monitoring Committee, 229
Desai M, 343
Diehr P, 267
Dippe S, 493
Dixon DO, 253
Drummond M, 479
Duggan C, 479
Duhaylongsod F, 601

Eagle K, 297
Eccles M, 479
Elbourne D, 149
Esposito R, 601
Exner DV, 319

Fawzi WW, 75
Fergusson D, 448
Feussner JR, 187
Fischer-Lapp K, 531
Fisher LD, 1, 16, 50
Floten H, 601
Frankel MR, 369
Franzosi MG, 194
Frederick M, 52
Freedman BI, 493
Freedman RR, 52
Freemantle N, 479
Freidlin B, 395

Garcia J, 149
Gaus W, 511
Gehan EA, 555
Geller NL, 52
George J, 280
George SL, 395
Geraci B, 121
Gifford DR, 369
Gimotty PA, 280
Goetghebeur E, 531
Goldman S, 297
Grover F, 601
Gu M, 423

Haines A, 479
Hanfelt JJ, 555
Hays MT, 187
Heitjan DF, 309
Hellemons BSP, 386
Henderson W, 601
Henderson WG, 297
Hershon K, 493
Hill R, 52
Hoffmeier M, 133
Högel J, 511
Holloway RG, 369
Huët C, 448
Hunsberger S, 52
Hunter DJ, 75

Ioannidis JPA, 253

Jacob RG, 52

Kaufmann P, 52
Kepner JL, 353
Knottnerus JA, 386
Korn EL, 395
Krieger S, 133
Krucoff M, 601
Krupski WC, 297

Lachin JM, 408
Lai TL, 423
Lakatos E, 121
Langenberg M, 386
Laupacis A, 448
Lavori PW, 187
LeBlanc M, 343
Lemmens TGJ, 386
Lesaffre E, 439
Levin J, 133
Lewis D, 601
Littooy F, 297
Liu PY, 343
Lodder J, 386
Lovato LC, 133
Lucke JC, 601

Mason J, 479
McAlister FA, 448
McFalls EO, 297
McIntosh M, 253
McNabb S, 297
Mooradian AD, 493
Moritz T, 297
Morrison DA, 601
Moyé L, 40, 121
Msamanga GI, 75
Murphy E, 601

Nazareth I, 479
Nicolis E, 194

Controlled Clinical Trials 20:620–621 (1999)
© Elsevier Science Inc. 1999
655 Avenue of the Americas, New York, NY 10010

0197-2456/99/$–see front matter

Nyman JA, 297

Palmer CR, 172
Patrick DL, 267
Petrovitch H, 133
Pett S, 601
Pledger G, 439
Probstfield JL, 121, 133

Ramanathan KB, 601
Raya T, 601
Robinson C, 601
Rosenberger WF, 172, 328
Russell I, 479

Sacks J, 601
Salmi LR, 448
Salsburg D, 453
Santoro E, 194
Sargent DJ, 242
Schnittman SM, 253
Schouten HJA, 386
Sedlis S, 601
Sethi G, 601
SHEP Cooperative Study Research Group, 133
Shuster JJ, 353
Slack RS, 555
Sloan JA, 242
Smith EA, 52
Snowdon C, 149
Spiegelman D, 75
Spinowitz BS, 493
Sugarman J, 187
Svolba G, 519

Talley JD, 601
Thompson B, 52
Tognoni G, 194

Urassa EJN, 75

VA Cooperative Study Group on CARP for Elective Vascular Surgery, 297
VA Cooperative Study Program, AWESOME Investigators, 601
van Ree JW, 386
Vermeer F, 386
Vernon S, 601
Vickrey BG, 369
Vogt T, 133

Walley T, 479
Ward HB, 297
Weichung JS, 469
Weiman D, 601
Wells GA, 448
Wigley FM, 52
Williamson J, 267
Wilson AC, 133
Wittes J, 121
Wolfe R, 547
Wood J, 479
Wuerth J-P, 493

Young P, 479

ELSEVIER

Subject Index for Volume 20

ABSOLUTE RISK REDUCTION
Comment on "The Number Needed to Treat," 439

ACCRUAL
Mass Mailing and Staff Experience in a *Total Recruitment Program for a* Clinical Trial: the SHEP Experience, 133

ADAPTIVE DESIGN
Ethics and Practice: Alternative Designs *for Phase III Randomized* Clinical Trials, 172
Randomized Play-the-Winner Clinical Trials: Review and *Recommendations*, 328

ADVANCED GLYCOSYLATION ENDPRODUCTS (AGEs)
Design and Baseline Characteristics for the Aminoguanidine Clinical *Trial in Overt Type 2 Diabetic* Nephropathy (ACTION II), 493

AGE-RELATED MACULAR DEGENERATION
The Age-Related Eye Disease Study *(AREDS): Design Implications* AREDS Report No.1, 573

AIDS TRIALS
Data and Safety Monitoring in the Concorde and Alpha Trials, 207
Data and Safety Monitoring in the Delta Trial, 229
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials:An Example from Primary *Pneumocystis carinii* Prophylaxis, 253

ALBUTEROL
Childhood Asthma Management *Program (CAMP): Design,* Rationale, and Methods, 91

ALLERGENS
Childhood Asthma Management Program (CAMP): Design, *Rationale, and Methods, 91*

ALLOCATION CONCEALMENT
Detecting Selection Bias in Randomized *Clinical Trials, 319*

ALPHA ALLOCATION
End-Point Interpretation in Clinical Trials: The Case for Discipline, 40

ALZHEIMER'S DISEASE
A Randomized Trial to Implement Practice Recommendations: *Design and Methods of the* Dementia Care Study, 369

AMETHOCAINE
Sample-Size Calculation for a Log- Transformed Outcome *Measure, 547*

AMINOGUANIDINE
Design and Baseline Characteristics for *the Aminoguanidine Clinical* Trial in Overt Type 2 Diabetic *Nephropathy (ACTION II), 493*

ANGINA
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients, 601
Survival *versus* Years of Healthy Life: Which Is More Powerful as a Study Outcome?, 267

Controlled Clinical Trials 20:622–631 (1999)
© Elsevier Science Inc. 1999
655 Avenue of the Americas, New York, NY 10010

0197-2456/99/$–see front matter

ANOVA MODEL
Comment on "Why Analysis of Variance is Inappropriate for Multiclinic Trials," 469
Why Analysis of Variance is Inappropriate for Multiclinic Trials, 453

ANTICOAGULATION
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386

ANTI-INFLAMMATORY AGENTS
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91

ATRIAL FIBRILLATION
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386

BAYESIAN METHODS
Data Monitoring Committees and Interim Monitoring Guidelines, 395
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

BEHAVIORAL TREATMENT
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study, 52

BETA-CAROTENE
The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No.1, 573

BINARY OUTCOMES
False Positive Rates of Randomized Phase II Designs, 343

BLINDNESS
The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No.1, 573

BLOCKING
Detecting Selection Bias in Randomized Clinical Trials, 319

BREAKPOINT REGRESSION
Statistical Quality Control in Clinical Trials, 519

BREAST CANCER
A Randomized Design of Repeated Binary Outcomes Used to Evaluate Continued Effectiveness of a Breast Cancer Control Intervention Strategy, 280

BRONCHODILATOR
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91

BUDESONIDE
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91

CARDIOVASCULAR DISEASE
Carvedilol and the FDA Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing, 16
Carvedilol and the Food and Drug Administration Approval Process: An Introduction, 1
Internet for Clinical Trials: Past, Present, and Future, 194
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients, 601
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386
Prophylactic Coronary Artery Revascularization for Elective Vascular Surgery: Study Design, 297
Survival versus Years of Healthy Life: Which Is More Powerful as a Study Outcome?, 267
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials, 408

CARVEDILOL
Carvedilol and the FDA Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing, 16

Carvedilol and the Food and Drug Administration Approval Process: An Introduction, 1
Comment on "Carvedilol and the Food and Drug Administration Approval Process," 50
End-Point Interpretation in Clinical Trials: The Case for Discipline, 40

CATARACT
The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No.1, 573

COMPLIANCE
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials, 531
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75

CONGESTIVE HEART FAILURE
Carvedilol and the FDA Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing, 16
Carvedilol and the Food and Drug Administration Approval Process: An Introduction, 1
End-Point Interpretation in Clinical Trials: The Case for Discipline, 40
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials, 408

CORONARY BYPASS
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients, 601

CRITICAL RATIONALISM
The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical Practice, 511

CROSSOVER DESIGN
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

CUSUM CHARTS
Statistical Quality Control in Clinical Trials, 519

DATA-DEPENDENT DESIGN
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

DEMENTIA
A Randomized Trial to Implement Practice Recommendations: Design and Methods of the Dementia Care Study, 369

DESIGN PAPERS
The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No.1, 573
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91
Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II), 493
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients, 601
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386
Prophylactic Coronary Artery Revascularization for Elective Vascular Surgery: Study Design, 297
A Randomized Trial of Evidence-Based Outreach (EBOR): Rationale and Design, 479
A Randomized Trial to Implement Practice Recommendations: Design and Methods of the Dementia Care Study, 369
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75

DIABETES MELLITUS
Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II), 493

DOUBLE-PARALLEL DESIGN
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study, 52

DRUG INVESTIGATION
The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical Practice, 511

DRUG LICENSING
Commentary: Confirmatory Trials–A New Approach?, 567
The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical Practice, 511

ECMO TRIAL
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 328
Randomized Play-the-Winner Clinical Trials: Review and Recommendations, 328

EDUCATIONAL OUTREACH
A Randomized Trial of Evidence-Based Outreach (EBOR): Rationale and Design, 479

ELDERLY
Mass Mailing and Staff Experience in a Total Recruitment Program for a Clinical Trial: the SHEP Experience, 133
Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program, 121
Survival *versus* Years of Healthy Life: Which Is More Powerful as a Study Outcome?, 267

ENDPOINTS INTERPRETATION
End-Point Interpretation in Clinical Trials: The Case for Discipline, 40

ENVIRONMENTAL EXPOSURE
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91

EPILEPSY
A Note on the Number Needed to Treat, 439

EQUIPOISE
Improving Informed Consent in Clinical Trials: A Duty to Experiment, 187
A Note on Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial (letter), 569

ESTIMATING EQUATIONS
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials, 531

ETHICS
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172
Improving Informed Consent in Clinical Trials: A Duty to Experiment, 187
Randomized Play-the-Winner Clinical Trials: Review and Recommendations, 328
Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial, 149

EVENT RATES
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials: An Example from Primary *Pneumocystis carinii* Prophylaxis, 253

EXPERT OPINION
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

FALSE POSITIVE RATE
False Positive Rates of Randomized Phase II Designs, 343

FDA DRUG APPROVAL
Carvedilol and the FDA Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing, 16
Carvedilol and the Food and Drug Administration Approval Process: An Introduction, 1

Comment on "Carvedilol and the FDA Approval Process," 50
The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical Practice, 511

FIXED UNEQUAL ALLOCATION
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

FULLY SEQUENTIAL DESIGN
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

GISSI
Internet for Clinical Trials: Past, Present, and Future, 194

GLUCOCORTICOIDS
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91

GROUP-SEQUENTIAL TESTS
Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and Interim Analyses, 423
Group Sequential Trials for Phase II Trials with Historical Controls, 353

HIERARCHICAL MODELS
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials: An Example from Primary *Pneumocystis carinii* Prophylaxis, 253

HISTORICAL CONTROLS
Group Sequential Trials for Phase II Trials with Historical Controls, 353

HIV INFECTION
Data and Safety Monitoring in the Concorde and Alpha Trials, 207
Data and Safety Monitoring in the Delta Trial, 229
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials: An Example from Primary *Pneumocystis carinii* Prophylaxis, 253

HYPERTENSION
Carvedilol and the Food and Drug Administration Approval Process: An Introduction, 1
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials, 531
Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program, 121

INFORMED CONSENT
Improving Informed Consent in Clinical Trials: A Duty to Experiment, 187
Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial, 149

INTENTION TO TREAT
Causal Inference in a Clinical Trial: A Comparative Example, 309
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials, 531

INTERIM ANALYSIS
Data Monitoring Committees and Interim Monitoring Guidelines, 395
Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and Interim Analyses, 423

INTERNET
Internet for Clinical Trials: Past, Present, and Future, 194

INTERRATER AGREEMENT
Assessing the Quality of Randomized Trials: Reliability of the Jadad Scale, 448

INTERVENTION STRATEGY
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study, 52

A Randomized Design of Repeated Binary Outcomes Used to Evaluate Continued Effectiveness of a Breast Cancer Control Intervention Strategy, 280

JADAD SCALE
Assessing the Quality of Randomized Trials: Reliability of the Jadad Scale, 448

KIDNEY FAILURE
Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II), 493

LIFE EXPECTANCY
Survival *versus* Years of Healthy Life: Which Is More Powerful as a Study Outcome?, 267

MAILING LISTS
Mass Mailing and Staff Experience in a Total Recruitment Program for a Clinical Trial: the SHEP Experience, 133

MAMMOGRAPHY
A Randomized Design of Repeated Binary Outcomes Used to Evaluate Continued Effectiveness of a Breast Cancer Control Intervention Strategy, 280

MATCHED-PAIRS ANALYSIS
Sample-Size Calculation for a Log-Transformed Outcome Measure, 547

META-ANALYSIS
Assessing the Quality of Randomized Trials: Reliability of the Jadad Scale, 448
A Note on the Number Needed to Treat, 439
Comment on "Why Analysis of Variance is Inappropriate for Multiclinic Trials," 469
Why Analysis of Variance is Inappropriate for Multiclinic Trials, 453

MISSING OBSERVATIONS
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials, 408

MONITORING
Commentary: Confirmatory Trials–A New Approach?, 567
Data and Safety Monitoring in the Concorde and Alpha Trials, 207
Data and Safety Monitoring in the Delta Trial, 229
Data Monitoring Committees and Interim Monitoring Guidelines, 395
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172
Statistical Quality Control in Clinical Trials, 519

MONTE CARLO SIMULATIONS
Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and Interim Analyses, 423

MULTICENTER TRIALS
Comment on "Why Analysis of Variance is Inappropriate for Multiclinic Trials," 469
Mass Mailing and Staff Experience in a Total Recruitment Program for a Clinical Trial: the SHEP Experience, 133
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials: An Example from Primary *Pneumocystis carinii* Prophylaxis, 253
Why Analysis of Variance is Inappropriate for Multiclinic Trials, 453

MULTIPLE SCLEROSIS
Causal Inference in a Clinical Trial: A Comparative Example, 309

MULTISTAGE DESIGN
A Modification of Simon's Optimal Design for Phase II Trials When the Criterion is Median Sample Size, 555
Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations, 242

NEONATAL TRIALS
A Note on Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial

(letter), 569
Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial, 149

NONCOMPLIANCE
Causal Inference in a Clinical Trial: A Comparative Example, 309
Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and Interim Analyses, 423
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials, 531

NONIGNORABLE MODEL
Causal Inference in a Clinical Trial: A Comparative Example, 309

NUMBER NEEDED TO TREAT
A Note on the Number Needed to Treat, 439

NUTRITION
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75

OUTCOME ASSESSMENT
A Randomized Trial of Evidence-Based Outreach (EBOR): Rationale and Design, 479

PAIN MEASUREMENT
Sample-Size Calculation for a Log-Transformed Outcome Measure, 547

PARENTAL PARTICIPATION
A Note on Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial (letter), 569
Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial, 149

PEARSON SKEW DISTRIBUTIONS
Why Analysis of Variance is Inappropriate for Multiclinic Trials, 453

PEDIATRIC ASTHMA
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91

PER-OBSERVATION ANALYSIS
Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations, 242

PHARMACOLOGICAL TREATMENT
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study, 52
A Randomized Trial of Evidence-Based Outreach (EBOR): Rationale and Design, 479

PHASE II TRIALS
False Positive Rates of Randomized Phase II Designs, 343
Group Sequential Trials for Phase II Trials with Historical Controls, 353
A Modification of Simon's Optimal Design for Phase II Trials When the Criterion is Median Sample Size, 555
Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations, 242

PHYSICIAN RESPONSIBILITY
End-Point Interpretation in Clinical Trials: The Case for Discipline, 40
A Randomized Trial to Implement Practice Recommendations: Design and Methods of the Dementia Care Study, 369

PLAY-THE-WINNER DESIGN
False Positive Rates of Randomized Phase II Designs, 343
Randomized Play-the-Winner Clinical Trials: Review and Recommendations, 328

PNEUMOCYSTIS CARINII
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials: An Example from Primary *Pneumocystis carinii* Prophylaxis, 253

PRACTICE GUIDELINES
End-Point Interpretation in Clinical Trials: The Case for Discipline, 40

A Randomized Trial of Evidence-Based Outreach (EBOR): Rationale and Design, 479
A Randomized Trial to Implement Practice Recommendations: Design and Methods of the Dementia Care Study, 369

PREVENTION
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386
A Randomized Design of Repeated Binary Outcomes Used to Evaluate Continued Effectiveness of a Breast Cancer Control Intervention Strategy, 280

PSYCHOLOGICAL TESTING
Analytical Implications of Changing Neuropsychological Test Versions During a Longitudinal Study Because of Aging in a Pediatric Cohort (letter), 476

QUALITY OF CARE
A Randomized Trial to Implement Practice Recommendations: Design and Methods of the Dementia Care Study, 369

QUALITY OF TRIALS
Assessing the Quality of Randomized Trials: Reliability of the Jadad Scale, 448
Commentary: Confirmatory Trials–A New Approach?, 567
The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical Practice, 511
Statistical Quality Control in Clinical Trials, 519

RANK ANALYSIS
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials, 408

RAYNAUD'S DISEASE
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study, 52

RECRUITMENT
Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods, 91
Mass Mailing and Staff Experience in a Total Recruitment Program for a Clinical Trial: the SHEP Experience, 133
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75
Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program, 121

RECURSIVE RESIDUALS
Statistical Quality Control in Clinical Trials, 519

REGRESSIVE LOGISTIC ANALYSIS
A Randomized Design of Repeated Binary Outcomes Used to Evaluate Continued Effectiveness of a Breast Cancer Control Intervention Strategy, 280

RESEARCH PARTICIPATION
Improving Informed Consent in Clinical Trials: A Duty to Experiment, 187

RESTRICTED TESTS
Why Analysis of Variance is Inappropriate for Multiclinic Trials, 453

REVASCULARIZATION
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients, 601

RISK FACTORS
A Note on the Number Needed to Treat, 439

RUBIN CAUSAL MODEL
Causal Inference in a Clinical Trial: A Comparative Example, 309

SAMPLE SIZE
Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and Interim Analyses, 423

Group Sequential Trials for Phase II Trials with Historical Controls, 353
A Modification of Simon's Optimal Design for Phase II Trials When the Criterion is Median Sample Size, 555
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial, 75
Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations, 242
Sample-Size Calculation for a Log-Transformed Outcome Measure, 547

SCREENING RULES
Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program, 121

SELECTION BIAS
Detecting Selection Bias in Randomized Clinical Trials, 319
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

SEQUENTIAL STOPPING RULES
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

SHEWART CHARTS
Statistical Quality Control in Clinical Trials, 519

SIMON'S OPTIMAL DESIGN
A Modification of Simon's Optimal Design for Phase II Trials When the Criterion is Median Sample Size, 555

STOCHASTIC CURTAILMENT
Data Monitoring Committees and Interim Monitoring Guidelines, 395

STRENGTH OF EVIDENCE
Carvedilol and the FDA Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing, 16

STROKE, RISK OF
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386

STRUCTURAL NESTED MEAN MODELS
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials, 531

SURROGATE MARKERS
Data and Safety Monitoring in the Concorde and Alpha Trials, 207

SURVIVAL
Data and Safety Monitoring in the Concorde and Alpha Trials, 207
Data and Safety Monitoring in the Delta Trial, 229
False Positive Rates of Randomized Phase II Designs, 343
Prophylactic Coronary Artery Revascularization for Elective Vascular Surgery: Study Design, 297
Survival *versus* Years of Healthy Life: Which Is More Powerful as a Study Outcome?, 267

THROMBOEMBOLISM
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design, 386

TREATMENT ALLOCATION
Comment on "Why Analysis of Variance is Inappropriate for Multiclinic Trials," 469
Detecting Selection Bias in Randomized Clinical Trials, 319
Randomized Play-the-Winner Clinical Trials: Review and Recommendations, 328
Sample-Size Calculation for a Log-Transformed Outcome Measure, 547
Why Analysis of Variance is Inappropriate for Multiclinic Trials, 453

TRIANGULAR TESTS
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

TWO-STAGE DESIGN
Group Sequential Trials for Phase II Trials with Historical Controls, 353

TYPE I ERROR
Carvedilol and the FDA Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing, 16

URN MODELS
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials, 172

VASCULAR SURGERY
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients, 601
Prophylactic Coronary Artery Revascularization for Elective Vascular Surgery: Study Design, 297

VESNARINONE
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials, 408

ZELEN RANDOMIZATION
A Note on Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial (letter), 569
Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial, 149

ZINC
The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No.1, 573

BOOK REVIEWS
Clinical Trials Dictionary: Terminology and Usage Recommendations, 66
Design and Analysis of Clinical Trials: Concepts and Methodologies, 365
Drug Regimen Compliance: Issues in Clinical Trials and Patient Management, 473
Management of Data in Clinical Trials, 295
Pharmaceutical Experimental Design, 472
Powerful Placebo,The, 64

SOFTWARE REVIEWS
Power and Precision, 202
WINKS Data Analysis Program, 68